January 17, 2017 9:29 AM ET


Company Overview of Boehringer Ingelheim Corporation

Company Overview

Boehringer Ingelheim Corporation, through its subsidiaries, discovers, develops, manufactures, and markets human and animal health care products in the United States. It offers cardiovascular, respiratory, HIV, immunology, central nervous system, and urology products; active pharmaceutical ingredients; oral liquids, tablets, and capsules; and products for the treatment of diseases in dogs, cats, horses, cattle, and swine. The company also provides over-the-counter health care products, including Dulcolax, which is used for occasional constipation and irregularity problems; Zantac that is used for the prevention and relief of heartburn; and Mirapex ER, a tablet for the signs and symptoms of i...

900 Ridgebury Road

P.O. Box 368

Ridgefield, CT 06877-0368

United States

Founded in 1984





Key Executives for Boehringer Ingelheim Corporation

Chief Executive Officer, President and Managing Director
Public Relations Manager
Chairman of the Board of Managing Directors
Compensation as of Fiscal Year 2016.

Boehringer Ingelheim Corporation Key Developments

Boehringer Ingelheim Corporation Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Boehringer Ingelheim Corporation Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Boehringer Ingelheim Completes Enrollment for Pivotal Phase III Trial

Boehringer Ingelheim announced it has completed enrollment for the pivotal Phase III trial of BI695501, a biosimilar candidate to adalimumab. This announcement was made following recent results from a Phase I trial that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. These Phase I data for BI695501 were discussed at the American College of Rheumatology /Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in San Francisco. The Phase III clinical trial is a randomized, double-blind, parallel arm, multiple dose, active comparator trial in patients who have been diagnosed with moderate to severe rheumatoid arthritis and are currently being treated with methotrexate. Each participant is randomized to receive either BI695501 or the U.S.-licensed reference product every two weeks for 48 weeks.

Boehringer Ingelheim Announces Results from Phase I Study of its Biosimilar Candidate for Adalimumab

Boehringer Ingelheim announced results from a Phase I study (NCT02045979) of its biosimilar candidate (BI695501) for adalimumab (AbbVie's Humira®), that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. These data were presented in a poster at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. The Phase I trial was a randomized, double-blind, single dose, parallel-arm study in healthy individuals: 327 healthy males between the ages of 18 and 55 participated; Each participant was randomized to receive one subcutaneous dose (40mg/0.8mL) of either BI695501, U.S.-licensed or EU-approved adalimumab. The study found that safety, tolerability and immunogenicity were comparable among the treatment groups.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Boehringer Ingelheim Corporation, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.